Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.
Latest
Popular

ASCO 2021: Renal cancer roundup

Dr Bradley McGregor - Dana-Farber Cancer Institute, Boston, USA
ASCO 2021: Renal cancer roundup ( Dr Bradley McGregor - Dana-Farber Cancer Institute, Boston, USA )
4 Jun 2021

KEYNOTE-564: Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for patients with renal cell carcinoma

Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA
KEYNOTE-564: Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for patients with renal cell carcinoma ( Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA )
4 Jun 2021

RELATIVITY-047: Relatlimab (RELA) plus nivolumab (NIVO) versus NIVO in first-line advanced melanoma

Dr Evan Jacob Lipson - Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, USA
RELATIVITY-047: Relatlimab (RELA) plus nivolumab (NIVO) versus NIVO in first-line advanced melanoma ( Dr Evan Jacob Lipson - Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, USA )
4 Jun 2021

Safety and efficacy of atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma

Prof Richard Finn - Geffen School of Medicine at UCLA, Los Angeles, USA
Safety and efficacy of atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma ( Prof Richard Finn - Geffen School of Medicine at UCLA, Los Angeles, USA )
13 Apr 2021

Cemiplimab plus ipilimumab for advanced NSCLC

Prof Byoung Yong Shim - The Catholic University of Korea, Suwon, South Korea
Cemiplimab plus ipilimumab for advanced NSCLC ( Prof Byoung Yong Shim - The Catholic University of Korea, Suwon, South Korea )
7 Apr 2021

Real world data and diagnostics in patients with NSCLC with EGFR exon 20 insertions

Prof Nicolas Girard, Prof Keith Kerr, Prof Frank Griesinger and Dr Antonio Passaro
Real world data and diagnostics in patients with NSCLC with EGFR exon 20 insertions ( Prof Nicolas Girard, Prof Keith Kerr, Prof Frank Griesinger and Dr Antonio Passaro )
29 Mar 2021

OncoAlert and ecancer weekly roundup for March 01 - 06, 2021

Dr Gil Morgan - Skåne University Hospital in Lund, Sweden
OncoAlert and ecancer weekly roundup for March 01 - 06, 2021 ( Dr Gil Morgan - Skåne University Hospital in Lund, Sweden )
8 Mar 2021

Oral HIF-2 α inhibitor MK-6482 in patients with advanced clear cell renal cell carcinoma

Dr Todd Michael Bauer - Sarah Cannon Research Institute and Tennessee Oncology, Nashville, USA
Oral HIF-2 α inhibitor MK-6482 in patients with advanced clear cell renal cell carcinoma ( Dr Todd Michael Bauer - Sarah Cannon Research Institute and Tennessee Oncology, Nashville, USA )
26 Feb 2021

Evolving medical treatment in advanced/recurrent endometrial cancer

Prof Robert Coleman - MD Anderson Cancer Center, Houston, USA
Evolving medical treatment in advanced/recurrent endometrial cancer ( Prof Robert Coleman - MD Anderson Cancer Center, Houston, USA )
18 Feb 2021

Neo-adjuvant therapy and surgical decision making in breast cancer

Dr Mehra Golshan - Yale School of Medicine, New Haven, USA
Neo-adjuvant therapy and surgical decision making in breast cancer ( Dr Mehra Golshan - Yale School of Medicine, New Haven, USA )
17 Feb 2021

Nurse's perspective on PARP inhibitors and personalised medicine in prostate cancer

Louisa Fleure - Guy's and St Thomas' NHS Trust, London, UK
Nurse's perspective on PARP inhibitors and personalised medicine in prostate cancer ( Louisa Fleure - Guy's and St Thomas' NHS Trust, London, UK )
17 Feb 2021

KEYNOTE-598: pembrolizumab with ipilimumab or placebo in patients with untreated metastatic NSCLC

Prof Michael Boyer - Chris O’Brien Lifehouse, Sydney, Australia
KEYNOTE-598: pembrolizumab with ipilimumab or placebo in patients with untreated metastatic NSCLC ( Prof Michael Boyer - Chris O’Brien Lifehouse, Sydney, Australia )
16 Feb 2021

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation